Axoltis synthetic peptide misses endpoint in phase 2 ALS trial
The company says it will continue developing the candidate despite the failed mid-stage readout.
PR
By Priya Raman · Science Reporter
Sep 15 04:47 ETSource: fiercebiotech.com
The wire
- 01Axoltis reported its synthetic peptide missed the mark in a phase 2 ALS study.
- 02A setback for peptide-based neuroprotection approaches in ALS.
- 03Axoltis plans to persevere, but revised trial design and next steps are unclear.
From the source
Read at news.google.comAxoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide